Welcome to Vicept

vicept - n. from Latin vita- life; and receptus (recipere) - to take back

A privately held specialty biopharmaceutical start-up focused on creating products for use in the largest and fastest growing sectors of the dermatology market.

Company founded with the mission to develop the first effective topically-applied treatment for the erythema (skin redness) associated with rosacea.

Innovator in the development of ()-adrenergic receptor technology pursuing indications which include the treatment and prevention of Rosacea, Actinic (Solar) Purpura and peri-procedural bruising of the skin.

Recent News

August 25, 2010
Vicept Therapeutics selected for Life Science Award.

View Article

August 05, 2010
Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea.

View Press Release

June 30, 2010
Vicept Therapeutics Secures $10 Million to Complete Series A Funding

View Press Release